AI assistant
ARIX BIOSCIENCE PLC Major Shareholding Notification 2018
4968_mrq_2018-08-17_f22c52f3-6737-4012-91dc-898e4fdc3634.html
Major Shareholding Notification
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
Arix Bioscience Plc - Holdings in Company and Lock-in Agreement
PR Newswire
London, August 17
Arix Bioscience plc
Holdings in Company and Lock-in Agreement
LONDON, 17 August 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, was notified today that Christopher Chipperton has today sold 3,000,000 ordinary shares of £0.00001 nominal value each ("Ordinary Shares") at a price of 155 pence per Ordinary Share (the "Disposal"). As a result of the Disposal Christopher Chipperton is interested, in aggregate, in 7,147,914 Ordinary Shares in the Company representing 5.3 per cent. of the Company's issued share capital.
Christopher Chipperton (the "Locked-in Party") has entered into a lock-in agreement (the “Agreement”) pursuant to which he shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the Disposal, save in certain very limited circumstances. The Agreement also provides that, save in certain limited circumstances, the Locked-in Party shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the first anniversary of the Disposal unless such disposal is effected through Stifel Nicolaus Europe Limited ("Stifel"), in order to ensure an orderly market in the Ordinary Shares ("Orderly Market Period"). Any disposal of Ordinary Shares during the Orderly Market Period will be in such a manner as Stifel may reasonably require with the view to the maintenance of an orderly market.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
Stifel Nicolaus Europe Limited (Joint broker)
Jonathan Senior, Ben Maddison, Chris Eccles
+44 (0)20 7107600
Jefferies International Limited (Joint broker)
Simon Hardy, Lee Morton, Christopher Binks
+44 (0)20 7029 8000
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
+44 (0)203 714 1787
Burns McClellan (US Media & IR Enquiries)
Lisa Burns, John Grimaldi, Bill Slattery Jr., Nancie Steinberg
+1 212-213-0006
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
